Blinatumomab Increases Disease-Free Survival for Children With Leukemia

By Karen Blum
Children with B-acute lymphoblastic leukemia (B-ALL) who received the monoclonal antibody blinatumomab (Blincyto, Amgen) along with standard chemotherapy were 61% less likely to have a relapse at three years, compared with similar children who received chemotherapy alone, according to new research.